Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Levosalbutamol Stories

2013-03-18 12:28:30

PITTSBURGH, March 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Specialty L.P. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levalbuterol Inhalation Solution USP, 0.31 mg/3 mL (0.0103%), 0.63 mg/3 mL (0.021%), and 1.25 mg/3 mL (0.042%), (Concentrate). This product is the generic version of Sunovion's Xopenex(® )Inhalation Solution, which is indicated for the...

2013-01-07 12:28:12

MIDLOTHIAN, Va., Jan. 7, 2013 /PRNewswire/ -- PARI Respiratory Equipment welcomes 2013 by launching a customer ordering website, PARIOrder.com. "We are pleased to serve thousands of home healthcare companies, medical supply distributors, pharmacies, hospitals, and physicians. Our customers share our commitment to providing the highest quality nebulizers and respiratory products to patients in need. PARI products, which are the most widely used in clinical trials for nebulized...

2012-08-20 02:31:50

PARSIPPANY, N.J., Aug. 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched an authorized generic version of Xopenex(® )(levalbuterol HCl) Inhalation Solution as part of an agreement with Sunovion Pharmaceuticals, Inc. Watson began shipping the product today. Xopenex(® )Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible...

2012-05-29 02:26:51

PITTSBURGH, May 29, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., that will resolve the parties' patent litigation in connection with Mylan Specialty's Abbreviated New Drug Application (ANDA) for Levalbuterol Hydrochloride (HCl) Inhalation Solution, 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. Levalbuterol HCl is the...

2012-02-10 16:17:00

PITTSBURGH, Feb. 10, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that a jury has rendered an unfavorable verdict in a patent infringement lawsuit filed by Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., against Mylan Inc., Mylan Pharmaceuticals Inc., Dey Inc. and Dey Pharma, L.P. in relation to Dey's Abbreviated New Drug Application (ANDA) for Levalbuterol Hydrochloride (HCl) Inhalation Solution, 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL...

2010-03-10 15:00:00

FORT LEE, N.J., March 10 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review. "We are pleased that the lurasidone NDA has been accepted for...

2009-12-02 17:52:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Markets for Asthma and COPD Drugs http://www.reportlinker.com/p0166826/Global-Markets-for-Asthma-and-COPD-Drugs.html Provides an in-depth analysis of the global market for medications that treat asthma and chronic obstructive pulmonary disease Contains global market forecasts through 2014 for medications that treat asthma and chronic obstructive pulmonary...

2009-09-01 09:26:00

PITTSBURGH, Sept. 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity. This product, which is indicated for the treatment or prevention of bronchospasm in patients over 6 years old with reversible obstructive airway disease, is the first...

2008-12-11 07:00:00

FAIRFAX, Va., Dec. 11 /PRNewswire-USNewswire/ -- Nancy Sander, president and founder of Allergy & Asthma Network Mothers of Asthmatics (AANMA) today urged committee members to preserve patient access to all forms of 12-hour bronchodilators at a joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee of the Food and Drug Administration held in Rockville, MD. Sander also requested the committee use...

2008-10-24 06:00:24

Sepracor Inc. (Nasdaq: SEPR) today announced that the EMEA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending to grant a marketing authorization for LUNIVIA(R) brand eszopiclone in the European Union (EU) for the treatment of insomnia. The EU labeling provides for patients who require longer-term therapy to be treated for up to six months, with the usual course of therapy for typical patients being short-term. LUNIVIA is marketed in the U.S....